Role of psychological suitability factors in the choice between short and long-term therapy for treatment of depressive and anxiety disorders

2007 ◽  
Vol 22 ◽  
pp. S234
Author(s):  
M.A. Laaksonen ◽  
P. Knekt ◽  
O. Lindfors
2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
K. Joutsenniemi ◽  
O. Lindfors ◽  
M. Laaksonen ◽  
P. Haaramo ◽  
P. Knekt

Background:Demographic factors have been shown to predict the outcome of short-term psychotherapy in the treatment of depressive and anxiety disorders. So far, however, information on the prediction for long- term therapy is missing. to be able to choose an optimal psychotherapy length for the patient, it is essential to know, which demographic factors predict different outcome in short- and long-term therapy.Aim:To compare the prediction of demographic factors on changes in psychiatric symptoms in short- and long-term psychotherapy.Methods:In the Helsinki Psychotherapy Study, 326 psychiatric outpatients, aged 20-46 years, and suffering from depressive or anxiety disorders, were randomly assigned to short-term therapy (short-term psychodynamic psychotherapy or solution-focused therapy combined) or long-term psychodynamic psychotherapy. the demographic factors (i.e. age, gender, education, income, and living arrangement) were assessed at baseline by a questionnaire. Psychiatric symptoms were assessed with the Symptom Check List, Global Severity Index (SCL-90-GSI) at baseline and 7 times during a 3-year follow-up.Results:Demographic factors were found to predict symptom development during follow-up irrespective of baseline symptom level. Female gender, being aged 25 or more, living with a spouse/partner, high education, and medium level personal income predicted benefiting sufficiently from short-term therapy, whereas being aged under 25, medium education, and living with other(s) than a partner or child(ren) predicted the need of long-term therapy.Conclusions:Demographic factors may be a useful tool in the selection of patients for short- and long term therapy.


2018 ◽  
Author(s):  
Shadi Doroudgar ◽  
Gurjit Bains

The underlying pathophysiology of anxiety disorders revolve around neurotransmitter transmission, the pharmacologic target of common medication treatments. Pharmacologic treatment of anxiety disorders generally consists of benzodiazepines for short-term relief of anxiety symptoms and antidepressants as a long-term therapy. Benzodiazepines use should be limited because of habit-forming properties, dependence, and risk of adverse effects. Antidepressants are the typically preferred initial agents for long-term use due to efficacy and lack of dependence. Anxiety disorders may occur as comorbidities with other psychiatric disorders. Other pharmacologic agents are utilized as alternative therapy for patients who do not respond to mainstay therapy or are not candidates for the treatment with antidepressants. This review contains 1 figure, 6 table and 77 references Key Points: anxiety disorders, benzodiazepines, generalized anxiety disorder, norepinephrine, panic disorder, social anxiety disorder, selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors


1987 ◽  
Vol 42 (2) ◽  
pp. 201-209 ◽  
Author(s):  
David M Salerno ◽  
Patricia J Sharkey ◽  
Gregory A Granrud ◽  
Richard W Asinger ◽  
Morrison Hodges

1995 ◽  
Vol 62 (2) ◽  
pp. 253-255
Author(s):  
G. Morgia ◽  
A. Saita ◽  
L. Fondacaro ◽  
B. Giammusso ◽  
M. Motta

Today there are many types of therapies (medical and surgical) in BPH treatment. The Authors suggest dividing BPH into two components: a dynamic phase and a static phase. On the basis of this, they used an association of finasteride and alfuzosin in short and long-term therapy. Provided the rationale is correct, the results in terms of improved flow and symptomatology score suggest that this is an optimal solution.


1989 ◽  
Vol 63 (17) ◽  
pp. 1273-1275 ◽  
Author(s):  
Patrick L. McCollam ◽  
Jerry L. Bauman ◽  
Karen J. Beckman ◽  
Robert J. Hariman

HYPERTENSION ◽  
2021 ◽  
Vol 14 (2) ◽  
pp. 12-29
Author(s):  
Yu.M. Sirenko

The lecture discusses the role of thiazide and thiazide-like diuretics, in particular chlorthalidone, in the modern treatment of arterial hypertension. The modern concepts about the mechanism of action of thiazide diuretics and chlorthalidone are presented. Differences in the degree of antihypertensive effect of hydrochlorothiazide and chlorthalidone are discussed. The results of large randomized trials SHEP, MRFIT, ALLHAT were analyzed, in which chlorthalidone therapy significantly reduced the risk of developing cardiovascular and cerebrovascular complications of hypertension. The effect of thiazide diuretics on glucose metabolism and the impact of carbohydrate metabolism disorders during treatment with chlorthalidone on the risk of cardiovascular complications was considered. The lecture also discusses the effect of chlorthalidone therapy on kidney function, the possibility of its use in chronic kidney disease. The data are presented on the prevention of resistant hypertension and chro-nic heart failure during long-term therapy of hypertension with chlorthalidone. The frequency and terms of the development of side effects of hypertension therapy with thiazide-like diuretics were also analyzed.


Sign in / Sign up

Export Citation Format

Share Document